British Columbia Expands Coverage Under PharmaCare Plan for New Drug for Hepatitis C
March 30, 2012
British Columbia's government has announced that its PharmaCare plan will begin providing boceprevir for hepatitis C patients who meet certain eligibility requirements. Known by the trade names Victrelis and Victrelis Triple, the medication is used in combination with other drugs and has been shown to boost cure rates by up to 25 percent. Boceprevir gained Health Canada approval last summer. Providing the drug will cost up to $50 million (US $50 million) during the next three years, the government said.
This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. Visit the CDC's website to find out more about their activities, publications and services.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)